- Home
- SKIL vs MCRB Comparison
SKIL vs MCRB Comparison
Compare SKIL & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKIL | MCRB |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 41.2M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SKIL | MCRB |
|---|---|---|
| Price | $3.14 | $1.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 49.0K | ★ 77.2K |
| Earning Date | 12-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | $1,648.67 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.05 | $1.35 |
| 52 Week High | $13.04 | $29.98 |
Technical Indicators
Market Signals| Indicator | SKIL | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 24.63 | 22.92 |
| Support Level | N/A | N/A |
| Resistance Level | $8.08 | $9.53 |
| Average True Range (ATR) | 0.42 | 0.24 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 5.44 | 9.39 |
Price Performance
Historical ComparisonAbout SKIL Skillsoft Corp.
Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.